Níveis elevados de ST2 no soro é um biomarcador para Cardiomiopatia em Distrofia Muscular de Duchenne
USA – nesta pesquisa os autores estudaram pacientes com cardiomiopatia na distrofia muscular de Duchenne. Os níveis de ST2 no soro dos pacientes com Duchenne é maior que nas pessoas que não tem a doença. Mas os níveis são significantemente maiores nos pacientes com Duchenne que apresentam cardiomiopatia.
O resumo em inglês pode ser lido abaixo:
(ACC, 2015) Elevated ST2 Serum Levels a Biomarker for Cardiomyopathy in Duchenne Muscular Dystrophy
Julia Anderson, Haeri Seol, Yetrib Hathout, Christopher Spurney, Children’s National Medical Center, Washington, DC, USA
Background: Duchenne muscular dystrophy (DMD) is a rare, fatal X-linked disorder characterized by the lack of dystrophin, a key sarcolemma muscle protein. Nearly 50% of DMD patients now die from cardiac related causes. The purpose of our research was to identify cardiac serum biomarkers associated with DMD cardiomyopathy.
Methods: Serum was collected from 30 participants enrolled in the Cooperative International Neuromuscular Research Group (CINRG) DMD Natural History study (clinicaltrials.gov: NCT00468832) from 5 clinical sites. Cardiomyopathy was defined as a reported shortening faction (SF) < 28% and/or ejection faction (EF) < 55%. Serum was analyzed via enzyme-linked immunosorbent assays (R&D Systems; Cloud-Clone Corp.) in duplicate using an xMark spectrometer (Bio-Rad Laboratories). ANOVAs (α < 0.05) were used to determine significance.
Results: There were no significant differences in ages between participants with DMD and cardiomyopathy; those with DMD and normal cardiac function; and normal controls. The DMD cardiomyopathy group had an EF=45±10% (mean±SD) / SF=25±2% and the DMD non-cardiomyopathy group had an EF=58±5% and SF=32±3% (p<0.01). Interleukin 1 receptor-like 1 (ST2) serum protein levels were significantly elevated in the DMD cardiomyopathy group [n=12; 35798±16918 pg/mL; p<0.01] compared to controls (n=4; 9940±6565 pg/mL). The DMD non-cardiomyopathy group also showed a significant 3 fold increase (n=12; 28837±17305 pg/mL; p<0.05) compared to controls. Matrix metallopeptidase 9 (MMP9) levels were significantly increased in both DMD groups compared to controls (p<0.02). No significant differences were seen in BNP, GAL3, CRP, LEP, TNC or TSP4 levels.
Conclusions: In conclusion, increased ST2 levels were found in serum of DMD patients compared to healthy volunteers and significantly elevated in DMD patients with cardiomyopathy. Future studies correlating cardiomyopathy with ST2 levels may allow for earlier detection and administration of cardioprotective therapies in DMD patients
